norfluoxetine has been researched along with Behavior Disorders in 6 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the pharmacokinetic profile of fluoxetine (FLX) and its major metabolite, norfluoxetine (NORFLX), in children and adolescent patients undergoing psychiatric treatment." | 2.70 | Fluoxetine pharmacokinetics in pediatric patients. ( Abrams, A; Biederman, J; Cohen, L; Faird, N; Neft, D; Sinha, V; Wilens, TE, 2002) |
| " A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0." | 1.31 | Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. ( Gatti, G; Guarneri, L; Jannuzzi, G; Magni, P; Pacifici, R; Perucca, E; Spina, E; Torta, R; Zuccaro, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sagahón-Azúa, J | 1 |
| Medellín-Garibay, SE | 1 |
| Chávez-Castillo, CE | 1 |
| González-Salinas, CG | 1 |
| Milán-Segovia, RDC | 1 |
| Romano-Moreno, S | 1 |
| Pinna, G | 1 |
| Costa, E | 1 |
| Guidotti, A | 1 |
| Jannuzzi, G | 1 |
| Gatti, G | 1 |
| Magni, P | 1 |
| Spina, E | 1 |
| Pacifici, R | 1 |
| Zuccaro, P | 1 |
| Torta, R | 1 |
| Guarneri, L | 1 |
| Perucca, E | 1 |
| LLerena, A | 2 |
| Dorado, P | 2 |
| Berecz, R | 2 |
| González, A | 1 |
| Jesús Norberto, M | 1 |
| de la Rubia, A | 1 |
| Cáceres, M | 1 |
| Wilens, TE | 1 |
| Cohen, L | 1 |
| Biederman, J | 1 |
| Abrams, A | 1 |
| Neft, D | 1 |
| Faird, N | 1 |
| Sinha, V | 1 |
| González, AP | 1 |
| Peñas-LLedó, EM | 1 |
1 review available for norfluoxetine and Behavior Disorders
| Article | Year |
|---|---|
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake.
Topics: Animals; Brain; Fluoxetine; gamma-Aminobutyric Acid; Humans; Mental Disorders; Mood Disorders; Pregn | 2009 |
2 trials available for norfluoxetine and Behavior Disorders
| Article | Year |
|---|---|
Fluoxetine pharmacokinetics in pediatric patients.
Topics: Adolescent; Child; Female; Fluoxetine; Humans; Male; Mental Disorders; Prospective Studies; Selectiv | 2002 |
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 C | 2004 |
3 other studies available for norfluoxetine and Behavior Disorders
| Article | Year |
|---|---|
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Topics: Adult; Antipsychotic Agents; Anxiety; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome | 2021 |
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Depression; Female; Fluoxetine; Humans; Male; Mental | 2002 |
Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.
Topics: Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; | 2003 |